CompletedPhase 4

Intravitreal Aflibercept for Submacular Hemorrhage

South Korea29 participantsStarted 2015-12

Plain-language summary

The prognosis of exudative age-related macular degeneration (AMD) accompanied by submacular hemorrhage is generally poor. A recently developed anti-VEGF agent eyeliaTM is also a useful treatment option for exudative AMD. However, one major limitation of VIEW study was that lack of data regarding eyes with submacular hemorrhage. The purpose of the present study was to evaluate the efficacy of Eylea in submacular hemorrhage secondary to exudative AMD.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. 50 years of older
✓. Newly diagnosed, treatment-naïve exudative AMD
✓. Fovea-involving submacular hemorrhage greater than 1 disc areas at diagnosis

Exclusion criteria

✕. History of previous treatment for neovascular AMD
✕. Greater than 15 disc diameter areas of hemorrhage extent
✕. History of vitreoretinal surgery
✕. History of glaucoma surgery, such as trabeculectomy or glaucoma implant surgery
✕. History of ocular steroid injection therapy within 1 month
✕. History of cataract surgery within 3 months
✕. Aphakia or anterior chamber intraocular lens implantation
✕. Spherical equivalents greater than -6.0 diopters

What they're measuring

Changes in Early Treatment of Diabetic Retinopathy Study visual acuity Score

Timeframe: Changes from baseline in visual acuity at 56 weeks

Trial details

NCT IDNCT03169660

SponsorKim's Eye Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-01-20

View on ClinicalTrials.gov More Exudative Age-related Macular Degeneration trials